nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Irinotecan—breast cancer	0.107	1	CbGbCtD
Raltegravir—CCR1—endometrium—breast cancer	0.0109	0.119	CbGeAlD
Raltegravir—CCR1—uterus—breast cancer	0.01	0.11	CbGeAlD
Raltegravir—CCR1—pituitary gland—breast cancer	0.00986	0.108	CbGeAlD
Raltegravir—CCR1—adipose tissue—breast cancer	0.00982	0.108	CbGeAlD
Raltegravir—CCR1—female reproductive system—breast cancer	0.00902	0.0989	CbGeAlD
Raltegravir—CCR1—adrenal gland—breast cancer	0.0088	0.0965	CbGeAlD
Raltegravir—CCR1—bone marrow—breast cancer	0.00852	0.0934	CbGeAlD
Raltegravir—CCR1—female gonad—breast cancer	0.00821	0.09	CbGeAlD
Raltegravir—CCR1—endocrine gland—breast cancer	0.00764	0.0837	CbGeAlD
Raltegravir—CCR1—lymph node—breast cancer	0.00528	0.0579	CbGeAlD
Raltegravir—UGT1A1—endocrine gland—breast cancer	0.00314	0.0344	CbGeAlD
Raltegravir—CCR1—Signaling Pathways—DLL1—breast cancer	0.00024	0.000904	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HIST1H2BK—breast cancer	0.000235	0.000887	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HIST1H2BC—breast cancer	0.000235	0.000887	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP3A4—breast cancer	0.000234	0.00088	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PDE4D—breast cancer	0.000233	0.000879	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GRB7—breast cancer	0.000233	0.000879	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CSF2—breast cancer	0.000232	0.000875	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP3A4—breast cancer	0.00023	0.000868	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP1B1—breast cancer	0.00023	0.000866	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TAB2—breast cancer	0.000229	0.000864	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—ITPR1—breast cancer	0.000228	0.00086	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—TGFBR2—breast cancer	0.000228	0.000858	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTP1—breast cancer	0.000228	0.000858	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CNR2—breast cancer	0.000227	0.000857	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL8—breast cancer	0.000227	0.000856	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MMP3—breast cancer	0.000227	0.000855	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP1B1—breast cancer	0.000226	0.000854	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—HMOX1—breast cancer	0.000225	0.000847	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—DKK1—breast cancer	0.000222	0.000836	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—VEGFC—breast cancer	0.00022	0.00083	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—NCOA1—breast cancer	0.000219	0.000826	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JAG2—breast cancer	0.000217	0.000817	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP19A1—breast cancer	0.000216	0.000814	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—breast cancer	0.000215	0.00081	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—WNT1—breast cancer	0.000214	0.000805	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PLA2G4A—breast cancer	0.000213	0.000803	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP19A1—breast cancer	0.000213	0.000803	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CSF2—breast cancer	0.000211	0.000794	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—breast cancer	0.000211	0.000794	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—HGF—breast cancer	0.000209	0.000789	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTM1—breast cancer	0.000209	0.000789	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—NRG1—breast cancer	0.000205	0.000774	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOTCH4—breast cancer	0.000203	0.000763	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GZMB—breast cancer	0.000201	0.000759	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—COMT—breast cancer	0.000201	0.000757	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—breast cancer	0.000201	0.000756	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTP1—breast cancer	0.0002	0.000753	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—COMT—breast cancer	0.000198	0.000746	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTP1—breast cancer	0.000197	0.000743	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AGTR2—breast cancer	0.000195	0.000737	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCL2—breast cancer	0.000195	0.000737	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTHLH—breast cancer	0.000193	0.000728	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BMP2—breast cancer	0.000193	0.000728	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EDNRB—breast cancer	0.000187	0.000705	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PGR—breast cancer	0.000185	0.000698	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—THBS1—breast cancer	0.000184	0.000695	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTM1—breast cancer	0.000184	0.000692	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTM1—breast cancer	0.000181	0.000682	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FLT1—breast cancer	0.000176	0.000663	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SQSTM1—breast cancer	0.000175	0.00066	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGF3—breast cancer	0.000175	0.00066	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CG—breast cancer	0.000174	0.000657	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP1A1—breast cancer	0.000174	0.000656	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JAG1—breast cancer	0.000173	0.000652	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PARP1—breast cancer	0.000172	0.000649	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOTCH3—breast cancer	0.000172	0.000649	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP1A1—breast cancer	0.000172	0.000647	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CALCA—breast cancer	0.00017	0.000641	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RPS6—breast cancer	0.000168	0.000634	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGF4—breast cancer	0.000167	0.000629	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCL12—breast cancer	0.000166	0.000626	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCR4—breast cancer	0.000166	0.000626	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PAK1—breast cancer	0.000163	0.000615	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TCF7L2—breast cancer	0.00016	0.000604	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKT2—breast cancer	0.000159	0.000601	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CG—breast cancer	0.000158	0.000597	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HSP90AA1—breast cancer	0.000154	0.000582	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOTCH2—breast cancer	0.000154	0.000582	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CD—breast cancer	0.000153	0.000578	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AGTR1—breast cancer	0.00015	0.000566	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PRL—breast cancer	0.00015	0.000566	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STK11—breast cancer	0.000148	0.000558	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ADAM10—breast cancer	0.000148	0.000558	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PLG—breast cancer	0.000146	0.000552	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AKT2—breast cancer	0.000145	0.000546	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGF10—breast cancer	0.000144	0.000543	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SYNJ2—breast cancer	0.00014	0.000528	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CD—breast cancer	0.000139	0.000524	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PDGFA—breast cancer	0.000139	0.000524	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TGFBR2—breast cancer	0.000137	0.000516	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ITPR1—breast cancer	0.000135	0.000508	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MMP3—breast cancer	0.000134	0.000505	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ERBB4—breast cancer	0.000134	0.000505	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STAT5A—breast cancer	0.000134	0.000505	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CB—breast cancer	0.000134	0.000503	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NDUFS3—breast cancer	0.00013	0.000491	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SMAD4—breast cancer	0.00013	0.000489	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IGF1R—breast cancer	0.000129	0.000486	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL8—breast cancer	0.000128	0.000484	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HES1—breast cancer	0.000127	0.000477	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PLA2G4A—breast cancer	0.000126	0.000475	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NCOR1—breast cancer	0.000126	0.000475	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CSF2—breast cancer	0.000124	0.000469	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGF1—breast cancer	0.000124	0.000469	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—RAF1—breast cancer	0.000124	0.000468	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NRG1—breast cancer	0.000124	0.000466	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—H2AFX—breast cancer	0.000123	0.000463	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL2—breast cancer	0.000123	0.000462	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CHST9—breast cancer	0.000122	0.000461	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—E2F1—breast cancer	0.000122	0.000459	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CB—breast cancer	0.000121	0.000457	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SPP1—breast cancer	0.000117	0.000441	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCL8—breast cancer	0.000117	0.000439	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—COX11—breast cancer	0.000116	0.000437	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ERBB3—breast cancer	0.000116	0.000436	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGFR2—breast cancer	0.000116	0.000436	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL2—breast cancer	0.000111	0.00042	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TERT—breast cancer	0.000111	0.000418	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGFR1—breast cancer	0.000108	0.000406	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HIF1A—breast cancer	0.000106	0.0004	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CDA—breast cancer	0.000106	0.0004	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SHMT1—breast cancer	0.000106	0.0004	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LEP—breast cancer	0.000104	0.000391	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CAV1—breast cancer	0.000103	0.000387	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLCO1B1—breast cancer	0.000102	0.000385	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC2A5—breast cancer	0.000102	0.000385	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KDR—breast cancer	0.000101	0.000383	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ESR1—breast cancer	9.89e-05	0.000373	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APRT—breast cancer	9.86e-05	0.000372	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FN1—breast cancer	9.77e-05	0.000368	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NFKBIA—breast cancer	9.65e-05	0.000364	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOTCH1—breast cancer	9.56e-05	0.00036	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—APC—breast cancer	9.35e-05	0.000352	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CG—breast cancer	9.35e-05	0.000352	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KIT—breast cancer	9.35e-05	0.000352	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ESRRA—breast cancer	9.27e-05	0.00035	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ANGPTL4—breast cancer	9.27e-05	0.00035	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EGF—breast cancer	9.24e-05	0.000348	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MAPK3—breast cancer	8.95e-05	0.000338	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GPI—breast cancer	8.79e-05	0.000331	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HADHB—breast cancer	8.79e-05	0.000331	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BRAF—breast cancer	8.79e-05	0.000331	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IGF1—breast cancer	8.56e-05	0.000323	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AKT2—breast cancer	8.55e-05	0.000322	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—TGFB1—breast cancer	8.53e-05	0.000322	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—EGFR—breast cancer	8.52e-05	0.000321	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALDH7A1—breast cancer	8.39e-05	0.000316	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALDH1A1—breast cancer	8.39e-05	0.000316	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CD—breast cancer	8.22e-05	0.00031	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CA—breast cancer	8.14e-05	0.000307	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SERPINE1—breast cancer	8.13e-05	0.000306	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—KRAS—breast cancer	8.05e-05	0.000303	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NME1—breast cancer	8.04e-05	0.000303	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—FHL2—breast cancer	8.04e-05	0.000303	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ADSL—breast cancer	8.04e-05	0.000303	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PHGDH—breast cancer	8.04e-05	0.000303	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—UMPS—breast cancer	8.04e-05	0.000303	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HPSE—breast cancer	7.88e-05	0.000297	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—BRIP1—breast cancer	7.88e-05	0.000297	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—LDHB—breast cancer	7.88e-05	0.000297	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOS3—breast cancer	7.76e-05	0.000293	CbGpPWpGaD
Raltegravir—Musculoskeletal discomfort—Docetaxel—breast cancer	7.76e-05	0.000145	CcSEcCtD
Raltegravir—Chills—Methotrexate—breast cancer	7.75e-05	0.000145	CcSEcCtD
Raltegravir—Headache—Irinotecan—breast cancer	7.72e-05	0.000144	CcSEcCtD
Raltegravir—Headache—Mitoxantrone—breast cancer	7.72e-05	0.000144	CcSEcCtD
Raltegravir—Insomnia—Docetaxel—breast cancer	7.7e-05	0.000144	CcSEcCtD
Raltegravir—Paraesthesia—Docetaxel—breast cancer	7.65e-05	0.000143	CcSEcCtD
Raltegravir—Erythema multiforme—Epirubicin—breast cancer	7.64e-05	0.000143	CcSEcCtD
Raltegravir—Alopecia—Methotrexate—breast cancer	7.63e-05	0.000142	CcSEcCtD
Raltegravir—Vomiting—Gemcitabine—breast cancer	7.63e-05	0.000142	CcSEcCtD
Raltegravir—Somnolence—Docetaxel—breast cancer	7.57e-05	0.000141	CcSEcCtD
Raltegravir—Mental disorder—Methotrexate—breast cancer	7.57e-05	0.000141	CcSEcCtD
Raltegravir—Rash—Gemcitabine—breast cancer	7.57e-05	0.000141	CcSEcCtD
Raltegravir—Dermatitis—Gemcitabine—breast cancer	7.56e-05	0.000141	CcSEcCtD
Raltegravir—Eye disorder—Epirubicin—breast cancer	7.56e-05	0.000141	CcSEcCtD
Raltegravir—Tinnitus—Epirubicin—breast cancer	7.54e-05	0.000141	CcSEcCtD
Raltegravir—Erythema—Methotrexate—breast cancer	7.52e-05	0.00014	CcSEcCtD
Raltegravir—Malnutrition—Methotrexate—breast cancer	7.52e-05	0.00014	CcSEcCtD
Raltegravir—Headache—Gemcitabine—breast cancer	7.52e-05	0.00014	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Capecitabine—breast cancer	7.51e-05	0.00014	CcSEcCtD
Raltegravir—Cardiac disorder—Epirubicin—breast cancer	7.5e-05	0.00014	CcSEcCtD
Raltegravir—Vomiting—Fluorouracil—breast cancer	7.5e-05	0.00014	CcSEcCtD
Raltegravir—Dyspepsia—Docetaxel—breast cancer	7.5e-05	0.00014	CcSEcCtD
Raltegravir—Hepatitis—Doxorubicin—breast cancer	7.48e-05	0.00014	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—HMMR—breast cancer	7.47e-05	0.000282	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCC1—breast cancer	7.47e-05	0.000282	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTA3—breast cancer	7.47e-05	0.000282	CbGpPWpGaD
Raltegravir—Insomnia—Capecitabine—breast cancer	7.46e-05	0.000139	CcSEcCtD
Raltegravir—Hypoaesthesia—Doxorubicin—breast cancer	7.44e-05	0.000139	CcSEcCtD
Raltegravir—Rash—Fluorouracil—breast cancer	7.44e-05	0.000139	CcSEcCtD
Raltegravir—Dermatitis—Fluorouracil—breast cancer	7.43e-05	0.000139	CcSEcCtD
Raltegravir—Paraesthesia—Capecitabine—breast cancer	7.4e-05	0.000138	CcSEcCtD
Raltegravir—Decreased appetite—Docetaxel—breast cancer	7.4e-05	0.000138	CcSEcCtD
Raltegravir—Hypersensitivity—Paclitaxel—breast cancer	7.4e-05	0.000138	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PIK3CA—breast cancer	7.39e-05	0.000279	CbGpPWpGaD
Raltegravir—Headache—Fluorouracil—breast cancer	7.39e-05	0.000138	CcSEcCtD
Raltegravir—Urinary tract disorder—Doxorubicin—breast cancer	7.39e-05	0.000138	CcSEcCtD
Raltegravir—Oedema peripheral—Doxorubicin—breast cancer	7.37e-05	0.000137	CcSEcCtD
Raltegravir—Dysgeusia—Methotrexate—breast cancer	7.36e-05	0.000137	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MDM2—breast cancer	7.36e-05	0.000278	CbGpPWpGaD
Raltegravir—Gastrointestinal disorder—Docetaxel—breast cancer	7.35e-05	0.000137	CcSEcCtD
Raltegravir—Connective tissue disorder—Doxorubicin—breast cancer	7.35e-05	0.000137	CcSEcCtD
Raltegravir—Fatigue—Docetaxel—breast cancer	7.34e-05	0.000137	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—RAF1—breast cancer	7.34e-05	0.000277	CbGpPWpGaD
Raltegravir—Angiopathy—Epirubicin—breast cancer	7.34e-05	0.000137	CcSEcCtD
Raltegravir—Urethral disorder—Doxorubicin—breast cancer	7.33e-05	0.000137	CcSEcCtD
Raltegravir—Nausea—Irinotecan—breast cancer	7.32e-05	0.000136	CcSEcCtD
Raltegravir—Nausea—Mitoxantrone—breast cancer	7.32e-05	0.000136	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—RELA—breast cancer	7.3e-05	0.000275	CbGpPWpGaD
Raltegravir—Immune system disorder—Epirubicin—breast cancer	7.3e-05	0.000136	CcSEcCtD
Raltegravir—Mediastinal disorder—Epirubicin—breast cancer	7.29e-05	0.000136	CcSEcCtD
Raltegravir—Constipation—Docetaxel—breast cancer	7.28e-05	0.000136	CcSEcCtD
Raltegravir—Pain—Docetaxel—breast cancer	7.28e-05	0.000136	CcSEcCtD
Raltegravir—Back pain—Methotrexate—breast cancer	7.27e-05	0.000136	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—ERBB2—breast cancer	7.26e-05	0.000274	CbGpPWpGaD
Raltegravir—Dyspepsia—Capecitabine—breast cancer	7.26e-05	0.000135	CcSEcCtD
Raltegravir—Chills—Epirubicin—breast cancer	7.25e-05	0.000135	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—PPARGC1B—breast cancer	7.24e-05	0.000273	CbGpPWpGaD
Raltegravir—Visual impairment—Doxorubicin—breast cancer	7.21e-05	0.000134	CcSEcCtD
Raltegravir—Asthenia—Paclitaxel—breast cancer	7.21e-05	0.000134	CcSEcCtD
Raltegravir—Decreased appetite—Capecitabine—breast cancer	7.17e-05	0.000134	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MTOR—breast cancer	7.16e-05	0.00027	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CB—breast cancer	7.16e-05	0.00027	CbGpPWpGaD
Raltegravir—Alopecia—Epirubicin—breast cancer	7.14e-05	0.000133	CcSEcCtD
Raltegravir—Nausea—Gemcitabine—breast cancer	7.13e-05	0.000133	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Capecitabine—breast cancer	7.12e-05	0.000133	CcSEcCtD
Raltegravir—Fatigue—Capecitabine—breast cancer	7.11e-05	0.000133	CcSEcCtD
Raltegravir—Pruritus—Paclitaxel—breast cancer	7.11e-05	0.000133	CcSEcCtD
Raltegravir—Mental disorder—Epirubicin—breast cancer	7.08e-05	0.000132	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—breast cancer	7.07e-05	0.000132	CcSEcCtD
Raltegravir—Constipation—Capecitabine—breast cancer	7.05e-05	0.000132	CcSEcCtD
Raltegravir—Pain—Capecitabine—breast cancer	7.05e-05	0.000132	CcSEcCtD
Raltegravir—Malnutrition—Epirubicin—breast cancer	7.04e-05	0.000131	CcSEcCtD
Raltegravir—Erythema—Epirubicin—breast cancer	7.04e-05	0.000131	CcSEcCtD
Raltegravir—Feeling abnormal—Docetaxel—breast cancer	7.02e-05	0.000131	CcSEcCtD
Raltegravir—Nausea—Fluorouracil—breast cancer	7.01e-05	0.000131	CcSEcCtD
Raltegravir—Eye disorder—Doxorubicin—breast cancer	6.99e-05	0.00013	CcSEcCtD
Raltegravir—Ill-defined disorder—Methotrexate—breast cancer	6.98e-05	0.00013	CcSEcCtD
Raltegravir—Tinnitus—Doxorubicin—breast cancer	6.97e-05	0.00013	CcSEcCtD
Raltegravir—Gastrointestinal pain—Docetaxel—breast cancer	6.96e-05	0.00013	CcSEcCtD
Raltegravir—Anaemia—Methotrexate—breast cancer	6.95e-05	0.00013	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—breast cancer	6.94e-05	0.00013	CcSEcCtD
Raltegravir—Flatulence—Epirubicin—breast cancer	6.94e-05	0.000129	CcSEcCtD
Raltegravir—Dysgeusia—Epirubicin—breast cancer	6.89e-05	0.000129	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CXCL8—breast cancer	6.88e-05	0.00026	CbGpPWpGaD
Raltegravir—Diarrhoea—Paclitaxel—breast cancer	6.87e-05	0.000128	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—HRAS—breast cancer	6.84e-05	0.000258	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTA4—breast cancer	6.84e-05	0.000258	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CA9—breast cancer	6.84e-05	0.000258	CbGpPWpGaD
Raltegravir—Nervousness—Epirubicin—breast cancer	6.84e-05	0.000128	CcSEcCtD
Raltegravir—Back pain—Epirubicin—breast cancer	6.81e-05	0.000127	CcSEcCtD
Raltegravir—Feeling abnormal—Capecitabine—breast cancer	6.79e-05	0.000127	CcSEcCtD
Raltegravir—Angiopathy—Doxorubicin—breast cancer	6.79e-05	0.000127	CcSEcCtD
Raltegravir—Malaise—Methotrexate—breast cancer	6.78e-05	0.000127	CcSEcCtD
Raltegravir—Immune system disorder—Doxorubicin—breast cancer	6.76e-05	0.000126	CcSEcCtD
Raltegravir—Vertigo—Methotrexate—breast cancer	6.76e-05	0.000126	CcSEcCtD
Raltegravir—Gastrointestinal pain—Capecitabine—breast cancer	6.74e-05	0.000126	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—breast cancer	6.74e-05	0.000126	CcSEcCtD
Raltegravir—Body temperature increased—Docetaxel—breast cancer	6.73e-05	0.000126	CcSEcCtD
Raltegravir—Abdominal pain—Docetaxel—breast cancer	6.73e-05	0.000126	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CDKN1B—breast cancer	6.72e-05	0.000253	CbGpPWpGaD
Raltegravir—Chills—Doxorubicin—breast cancer	6.71e-05	0.000125	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTA2—breast cancer	6.66e-05	0.000251	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GPX2—breast cancer	6.66e-05	0.000251	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKT1—breast cancer	6.65e-05	0.000251	CbGpPWpGaD
Raltegravir—Dizziness—Paclitaxel—breast cancer	6.64e-05	0.000124	CcSEcCtD
Raltegravir—Alopecia—Doxorubicin—breast cancer	6.61e-05	0.000123	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CASP3—breast cancer	6.59e-05	0.000248	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SULT1A1—breast cancer	6.58e-05	0.000248	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GPX4—breast cancer	6.58e-05	0.000248	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL2—breast cancer	6.58e-05	0.000248	CbGpPWpGaD
Raltegravir—Cough—Methotrexate—breast cancer	6.56e-05	0.000122	CcSEcCtD
Raltegravir—Mental disorder—Doxorubicin—breast cancer	6.55e-05	0.000122	CcSEcCtD
Raltegravir—Urticaria—Capecitabine—breast cancer	6.55e-05	0.000122	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—IL6—breast cancer	6.55e-05	0.000247	CbGpPWpGaD
Raltegravir—Ill-defined disorder—Epirubicin—breast cancer	6.53e-05	0.000122	CcSEcCtD
Raltegravir—Body temperature increased—Capecitabine—breast cancer	6.52e-05	0.000122	CcSEcCtD
Raltegravir—Abdominal pain—Capecitabine—breast cancer	6.52e-05	0.000122	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—breast cancer	6.51e-05	0.000121	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—breast cancer	6.51e-05	0.000121	CcSEcCtD
Raltegravir—Anaemia—Epirubicin—breast cancer	6.5e-05	0.000121	CcSEcCtD
Raltegravir—Agitation—Epirubicin—breast cancer	6.47e-05	0.000121	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—IDH1—breast cancer	6.43e-05	0.000242	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTA1—breast cancer	6.43e-05	0.000242	CbGpPWpGaD
Raltegravir—Flatulence—Doxorubicin—breast cancer	6.42e-05	0.00012	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CCND1—breast cancer	6.41e-05	0.000242	CbGpPWpGaD
Raltegravir—Arthralgia—Methotrexate—breast cancer	6.4e-05	0.000119	CcSEcCtD
Raltegravir—Chest pain—Methotrexate—breast cancer	6.4e-05	0.000119	CcSEcCtD
Raltegravir—Myalgia—Methotrexate—breast cancer	6.4e-05	0.000119	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—JUN—breast cancer	6.4e-05	0.000241	CbGpPWpGaD
Raltegravir—Vomiting—Paclitaxel—breast cancer	6.39e-05	0.000119	CcSEcCtD
Raltegravir—Dysgeusia—Doxorubicin—breast cancer	6.38e-05	0.000119	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	6.36e-05	0.000119	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NAT2—breast cancer	6.35e-05	0.00024	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CTNNB1—breast cancer	6.35e-05	0.000239	CbGpPWpGaD
Raltegravir—Malaise—Epirubicin—breast cancer	6.35e-05	0.000118	CcSEcCtD
Raltegravir—Rash—Paclitaxel—breast cancer	6.33e-05	0.000118	CcSEcCtD
Raltegravir—Dermatitis—Paclitaxel—breast cancer	6.33e-05	0.000118	CcSEcCtD
Raltegravir—Discomfort—Methotrexate—breast cancer	6.33e-05	0.000118	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—breast cancer	6.32e-05	0.000118	CcSEcCtD
Raltegravir—Vertigo—Epirubicin—breast cancer	6.32e-05	0.000118	CcSEcCtD
Raltegravir—Back pain—Doxorubicin—breast cancer	6.3e-05	0.000117	CcSEcCtD
Raltegravir—Headache—Paclitaxel—breast cancer	6.29e-05	0.000117	CcSEcCtD
Raltegravir—Hypersensitivity—Docetaxel—breast cancer	6.27e-05	0.000117	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MMP9—breast cancer	6.23e-05	0.000235	CbGpPWpGaD
Raltegravir—Palpitations—Epirubicin—breast cancer	6.22e-05	0.000116	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CDKN1A—breast cancer	6.2e-05	0.000234	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTEN—breast cancer	6.19e-05	0.000233	CbGpPWpGaD
Raltegravir—Confusional state—Methotrexate—breast cancer	6.19e-05	0.000115	CcSEcCtD
Raltegravir—Cough—Epirubicin—breast cancer	6.14e-05	0.000115	CcSEcCtD
Raltegravir—Asthenia—Docetaxel—breast cancer	6.11e-05	0.000114	CcSEcCtD
Raltegravir—Infection—Methotrexate—breast cancer	6.1e-05	0.000114	CcSEcCtD
Raltegravir—Hypertension—Epirubicin—breast cancer	6.08e-05	0.000113	CcSEcCtD
Raltegravir—Hypersensitivity—Capecitabine—breast cancer	6.07e-05	0.000113	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MAPK8—breast cancer	6.06e-05	0.000228	CbGpPWpGaD
Raltegravir—Ill-defined disorder—Doxorubicin—breast cancer	6.04e-05	0.000113	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—AKT1—breast cancer	6.04e-05	0.000228	CbGpPWpGaD
Raltegravir—Pruritus—Docetaxel—breast cancer	6.02e-05	0.000112	CcSEcCtD
Raltegravir—Nervous system disorder—Methotrexate—breast cancer	6.02e-05	0.000112	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—breast cancer	6.02e-05	0.000112	CcSEcCtD
Raltegravir—Thrombocytopenia—Methotrexate—breast cancer	6.01e-05	0.000112	CcSEcCtD
Raltegravir—Arthralgia—Epirubicin—breast cancer	5.99e-05	0.000112	CcSEcCtD
Raltegravir—Chest pain—Epirubicin—breast cancer	5.99e-05	0.000112	CcSEcCtD
Raltegravir—Myalgia—Epirubicin—breast cancer	5.99e-05	0.000112	CcSEcCtD
Raltegravir—Agitation—Doxorubicin—breast cancer	5.98e-05	0.000112	CcSEcCtD
Raltegravir—Anxiety—Epirubicin—breast cancer	5.97e-05	0.000111	CcSEcCtD
Raltegravir—Nausea—Paclitaxel—breast cancer	5.97e-05	0.000111	CcSEcCtD
Raltegravir—Skin disorder—Methotrexate—breast cancer	5.96e-05	0.000111	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	5.95e-05	0.000111	CcSEcCtD
Raltegravir—Hyperhidrosis—Methotrexate—breast cancer	5.93e-05	0.000111	CcSEcCtD
Raltegravir—Discomfort—Epirubicin—breast cancer	5.92e-05	0.00011	CcSEcCtD
Raltegravir—Asthenia—Capecitabine—breast cancer	5.92e-05	0.00011	CcSEcCtD
Raltegravir—Malaise—Doxorubicin—breast cancer	5.87e-05	0.00011	CcSEcCtD
Raltegravir—Dry mouth—Epirubicin—breast cancer	5.86e-05	0.000109	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—breast cancer	5.85e-05	0.000109	CcSEcCtD
Raltegravir—Pruritus—Capecitabine—breast cancer	5.83e-05	0.000109	CcSEcCtD
Raltegravir—Diarrhoea—Docetaxel—breast cancer	5.83e-05	0.000109	CcSEcCtD
Raltegravir—Confusional state—Epirubicin—breast cancer	5.79e-05	0.000108	CcSEcCtD
Raltegravir—Palpitations—Doxorubicin—breast cancer	5.75e-05	0.000107	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SRC—breast cancer	5.74e-05	0.000216	CbGpPWpGaD
Raltegravir—Infection—Epirubicin—breast cancer	5.71e-05	0.000106	CcSEcCtD
Raltegravir—Cough—Doxorubicin—breast cancer	5.68e-05	0.000106	CcSEcCtD
Raltegravir—Diarrhoea—Capecitabine—breast cancer	5.64e-05	0.000105	CcSEcCtD
Raltegravir—Nervous system disorder—Epirubicin—breast cancer	5.63e-05	0.000105	CcSEcCtD
Raltegravir—Dizziness—Docetaxel—breast cancer	5.63e-05	0.000105	CcSEcCtD
Raltegravir—Thrombocytopenia—Epirubicin—breast cancer	5.62e-05	0.000105	CcSEcCtD
Raltegravir—Hypertension—Doxorubicin—breast cancer	5.62e-05	0.000105	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Methotrexate—breast cancer	5.59e-05	0.000104	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—VEGFA—breast cancer	5.59e-05	0.000211	CbGpPWpGaD
Raltegravir—Skin disorder—Epirubicin—breast cancer	5.58e-05	0.000104	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—MED12—breast cancer	5.57e-05	0.00021	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—DPYD—breast cancer	5.57e-05	0.00021	CbGpPWpGaD
Raltegravir—Hyperhidrosis—Epirubicin—breast cancer	5.55e-05	0.000104	CcSEcCtD
Raltegravir—Insomnia—Methotrexate—breast cancer	5.55e-05	0.000104	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—breast cancer	5.54e-05	0.000103	CcSEcCtD
Raltegravir—Myalgia—Doxorubicin—breast cancer	5.54e-05	0.000103	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—breast cancer	5.54e-05	0.000103	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—STAT3—breast cancer	5.54e-05	0.000209	CbGpPWpGaD
Raltegravir—Anxiety—Doxorubicin—breast cancer	5.52e-05	0.000103	CcSEcCtD
Raltegravir—Paraesthesia—Methotrexate—breast cancer	5.51e-05	0.000103	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	5.51e-05	0.000103	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ALDOA—breast cancer	5.49e-05	0.000207	CbGpPWpGaD
Raltegravir—Discomfort—Doxorubicin—breast cancer	5.48e-05	0.000102	CcSEcCtD
Raltegravir—Somnolence—Methotrexate—breast cancer	5.46e-05	0.000102	CcSEcCtD
Raltegravir—Dizziness—Capecitabine—breast cancer	5.45e-05	0.000102	CcSEcCtD
Raltegravir—Dry mouth—Doxorubicin—breast cancer	5.42e-05	0.000101	CcSEcCtD
Raltegravir—Vomiting—Docetaxel—breast cancer	5.41e-05	0.000101	CcSEcCtD
Raltegravir—Dyspepsia—Methotrexate—breast cancer	5.4e-05	0.000101	CcSEcCtD
Raltegravir—Rash—Docetaxel—breast cancer	5.37e-05	0.0001	CcSEcCtD
Raltegravir—Dermatitis—Docetaxel—breast cancer	5.36e-05	0.0001	CcSEcCtD
Raltegravir—Confusional state—Doxorubicin—breast cancer	5.36e-05	0.0001	CcSEcCtD
Raltegravir—Decreased appetite—Methotrexate—breast cancer	5.34e-05	9.95e-05	CcSEcCtD
Raltegravir—Headache—Docetaxel—breast cancer	5.33e-05	9.95e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NCOA3—breast cancer	5.33e-05	0.000201	CbGpPWpGaD
Raltegravir—Gastrointestinal disorder—Methotrexate—breast cancer	5.3e-05	9.88e-05	CcSEcCtD
Raltegravir—Fatigue—Methotrexate—breast cancer	5.29e-05	9.87e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MAPK3—breast cancer	5.29e-05	0.000199	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC2A2—breast cancer	5.29e-05	0.000199	CbGpPWpGaD
Raltegravir—Infection—Doxorubicin—breast cancer	5.28e-05	9.85e-05	CcSEcCtD
Raltegravir—Pain—Methotrexate—breast cancer	5.25e-05	9.79e-05	CcSEcCtD
Raltegravir—Vomiting—Capecitabine—breast cancer	5.24e-05	9.78e-05	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Epirubicin—breast cancer	5.23e-05	9.76e-05	CcSEcCtD
Raltegravir—Nervous system disorder—Doxorubicin—breast cancer	5.21e-05	9.72e-05	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—breast cancer	5.2e-05	9.71e-05	CcSEcCtD
Raltegravir—Rash—Capecitabine—breast cancer	5.2e-05	9.7e-05	CcSEcCtD
Raltegravir—Insomnia—Epirubicin—breast cancer	5.2e-05	9.69e-05	CcSEcCtD
Raltegravir—Dermatitis—Capecitabine—breast cancer	5.19e-05	9.69e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ABCG2—breast cancer	5.18e-05	0.000195	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—MTR—breast cancer	5.18e-05	0.000195	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CPT1A—breast cancer	5.18e-05	0.000195	CbGpPWpGaD
Raltegravir—Headache—Capecitabine—breast cancer	5.17e-05	9.63e-05	CcSEcCtD
Raltegravir—Skin disorder—Doxorubicin—breast cancer	5.16e-05	9.63e-05	CcSEcCtD
Raltegravir—Paraesthesia—Epirubicin—breast cancer	5.16e-05	9.62e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MYC—breast cancer	5.14e-05	0.000194	CbGpPWpGaD
Raltegravir—Hyperhidrosis—Doxorubicin—breast cancer	5.14e-05	9.58e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TGFB1—breast cancer	5.13e-05	0.000193	CbGpPWpGaD
Raltegravir—Somnolence—Epirubicin—breast cancer	5.11e-05	9.53e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—HPGDS—breast cancer	5.08e-05	0.000192	CbGpPWpGaD
Raltegravir—Nausea—Docetaxel—breast cancer	5.06e-05	9.44e-05	CcSEcCtD
Raltegravir—Feeling abnormal—Methotrexate—breast cancer	5.06e-05	9.43e-05	CcSEcCtD
Raltegravir—Dyspepsia—Epirubicin—breast cancer	5.06e-05	9.43e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—HBA1—breast cancer	5.05e-05	0.00019	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EGFR—breast cancer	5.03e-05	0.00019	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Methotrexate—breast cancer	5.02e-05	9.36e-05	CcSEcCtD
Raltegravir—Decreased appetite—Epirubicin—breast cancer	4.99e-05	9.31e-05	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Epirubicin—breast cancer	4.96e-05	9.25e-05	CcSEcCtD
Raltegravir—Fatigue—Epirubicin—breast cancer	4.95e-05	9.24e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTT1—breast cancer	4.93e-05	0.000186	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ACHE—breast cancer	4.93e-05	0.000186	CbGpPWpGaD
Raltegravir—Constipation—Epirubicin—breast cancer	4.91e-05	9.16e-05	CcSEcCtD
Raltegravir—Pain—Epirubicin—breast cancer	4.91e-05	9.16e-05	CcSEcCtD
Raltegravir—Nausea—Capecitabine—breast cancer	4.9e-05	9.14e-05	CcSEcCtD
Raltegravir—Urticaria—Methotrexate—breast cancer	4.88e-05	9.1e-05	CcSEcCtD
Raltegravir—Abdominal pain—Methotrexate—breast cancer	4.85e-05	9.05e-05	CcSEcCtD
Raltegravir—Body temperature increased—Methotrexate—breast cancer	4.85e-05	9.05e-05	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—breast cancer	4.84e-05	9.03e-05	CcSEcCtD
Raltegravir—Insomnia—Doxorubicin—breast cancer	4.81e-05	8.97e-05	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—breast cancer	4.77e-05	8.9e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—KRAS—breast cancer	4.75e-05	0.000179	CbGpPWpGaD
Raltegravir—Feeling abnormal—Epirubicin—breast cancer	4.73e-05	8.83e-05	CcSEcCtD
Raltegravir—Somnolence—Doxorubicin—breast cancer	4.72e-05	8.81e-05	CcSEcCtD
Raltegravir—Gastrointestinal pain—Epirubicin—breast cancer	4.7e-05	8.76e-05	CcSEcCtD
Raltegravir—Dyspepsia—Doxorubicin—breast cancer	4.68e-05	8.73e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP17A1—breast cancer	4.66e-05	0.000176	CbGpPWpGaD
Raltegravir—Decreased appetite—Doxorubicin—breast cancer	4.62e-05	8.62e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ENO1—breast cancer	4.62e-05	0.000174	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS1—breast cancer	4.62e-05	0.000174	CbGpPWpGaD
Raltegravir—Gastrointestinal disorder—Doxorubicin—breast cancer	4.59e-05	8.56e-05	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—breast cancer	4.58e-05	8.55e-05	CcSEcCtD
Raltegravir—Urticaria—Epirubicin—breast cancer	4.56e-05	8.51e-05	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—breast cancer	4.54e-05	8.48e-05	CcSEcCtD
Raltegravir—Pain—Doxorubicin—breast cancer	4.54e-05	8.48e-05	CcSEcCtD
Raltegravir—Body temperature increased—Epirubicin—breast cancer	4.54e-05	8.47e-05	CcSEcCtD
Raltegravir—Abdominal pain—Epirubicin—breast cancer	4.54e-05	8.47e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP2D6—breast cancer	4.53e-05	0.000171	CbGpPWpGaD
Raltegravir—Hypersensitivity—Methotrexate—breast cancer	4.52e-05	8.44e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NCOA2—breast cancer	4.44e-05	0.000168	CbGpPWpGaD
Raltegravir—Asthenia—Methotrexate—breast cancer	4.4e-05	8.21e-05	CcSEcCtD
Raltegravir—Feeling abnormal—Doxorubicin—breast cancer	4.38e-05	8.17e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PIK3CA—breast cancer	4.37e-05	0.000165	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Doxorubicin—breast cancer	4.35e-05	8.11e-05	CcSEcCtD
Raltegravir—Pruritus—Methotrexate—breast cancer	4.34e-05	8.1e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—FASN—breast cancer	4.31e-05	0.000163	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—BCHE—breast cancer	4.29e-05	0.000162	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC5A5—breast cancer	4.24e-05	0.00016	CbGpPWpGaD
Raltegravir—Hypersensitivity—Epirubicin—breast cancer	4.23e-05	7.89e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TP53—breast cancer	4.22e-05	0.000159	CbGpPWpGaD
Raltegravir—Urticaria—Doxorubicin—breast cancer	4.22e-05	7.88e-05	CcSEcCtD
Raltegravir—Body temperature increased—Doxorubicin—breast cancer	4.2e-05	7.84e-05	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—breast cancer	4.2e-05	7.84e-05	CcSEcCtD
Raltegravir—Diarrhoea—Methotrexate—breast cancer	4.2e-05	7.83e-05	CcSEcCtD
Raltegravir—Asthenia—Epirubicin—breast cancer	4.12e-05	7.69e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NQO1—breast cancer	4.1e-05	0.000154	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC2A1—breast cancer	4.1e-05	0.000154	CbGpPWpGaD
Raltegravir—Pruritus—Epirubicin—breast cancer	4.06e-05	7.58e-05	CcSEcCtD
Raltegravir—Dizziness—Methotrexate—breast cancer	4.06e-05	7.57e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—HRAS—breast cancer	4.04e-05	0.000152	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP3A4—breast cancer	3.99e-05	0.000151	CbGpPWpGaD
Raltegravir—Diarrhoea—Epirubicin—breast cancer	3.93e-05	7.33e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP1B1—breast cancer	3.93e-05	0.000148	CbGpPWpGaD
Raltegravir—Hypersensitivity—Doxorubicin—breast cancer	3.92e-05	7.3e-05	CcSEcCtD
Raltegravir—Vomiting—Methotrexate—breast cancer	3.9e-05	7.28e-05	CcSEcCtD
Raltegravir—Rash—Methotrexate—breast cancer	3.87e-05	7.22e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IL6—breast cancer	3.87e-05	0.000146	CbGpPWpGaD
Raltegravir—Dermatitis—Methotrexate—breast cancer	3.87e-05	7.21e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—HSP90AA1—breast cancer	3.85e-05	0.000145	CbGpPWpGaD
Raltegravir—Headache—Methotrexate—breast cancer	3.85e-05	7.17e-05	CcSEcCtD
Raltegravir—Asthenia—Doxorubicin—breast cancer	3.81e-05	7.11e-05	CcSEcCtD
Raltegravir—Dizziness—Epirubicin—breast cancer	3.8e-05	7.09e-05	CcSEcCtD
Raltegravir—Pruritus—Doxorubicin—breast cancer	3.76e-05	7.01e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NCOA1—breast cancer	3.75e-05	0.000141	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—STK11—breast cancer	3.69e-05	0.000139	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP19A1—breast cancer	3.69e-05	0.000139	CbGpPWpGaD
Raltegravir—Vomiting—Epirubicin—breast cancer	3.65e-05	6.81e-05	CcSEcCtD
Raltegravir—Nausea—Methotrexate—breast cancer	3.65e-05	6.8e-05	CcSEcCtD
Raltegravir—Diarrhoea—Doxorubicin—breast cancer	3.64e-05	6.78e-05	CcSEcCtD
Raltegravir—Rash—Epirubicin—breast cancer	3.62e-05	6.76e-05	CcSEcCtD
Raltegravir—Dermatitis—Epirubicin—breast cancer	3.62e-05	6.75e-05	CcSEcCtD
Raltegravir—Headache—Epirubicin—breast cancer	3.6e-05	6.71e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—AKT1—breast cancer	3.57e-05	0.000134	CbGpPWpGaD
Raltegravir—Dizziness—Doxorubicin—breast cancer	3.51e-05	6.56e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—COMT—breast cancer	3.43e-05	0.000129	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTP1—breast cancer	3.42e-05	0.000129	CbGpPWpGaD
Raltegravir—Nausea—Epirubicin—breast cancer	3.41e-05	6.36e-05	CcSEcCtD
Raltegravir—Vomiting—Doxorubicin—breast cancer	3.38e-05	6.3e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—HMOX1—breast cancer	3.37e-05	0.000127	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ITPR1—breast cancer	3.36e-05	0.000127	CbGpPWpGaD
Raltegravir—Rash—Doxorubicin—breast cancer	3.35e-05	6.25e-05	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—breast cancer	3.35e-05	6.25e-05	CcSEcCtD
Raltegravir—Headache—Doxorubicin—breast cancer	3.33e-05	6.21e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ABCB1—breast cancer	3.23e-05	0.000122	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TYMS—breast cancer	3.18e-05	0.00012	CbGpPWpGaD
Raltegravir—Nausea—Doxorubicin—breast cancer	3.16e-05	5.89e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NCOR1—breast cancer	3.14e-05	0.000118	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PLA2G4A—breast cancer	3.14e-05	0.000118	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTM1—breast cancer	3.14e-05	0.000118	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GPX1—breast cancer	3.01e-05	0.000113	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP1A1—breast cancer	2.98e-05	0.000112	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ERCC2—breast cancer	2.95e-05	0.000111	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—MTHFR—breast cancer	2.77e-05	0.000105	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CAV1—breast cancer	2.56e-05	9.65e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CG—breast cancer	2.33e-05	8.79e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CD—breast cancer	2.05e-05	7.72e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALB—breast cancer	2.02e-05	7.62e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NOS3—breast cancer	1.93e-05	7.29e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CB—breast cancer	1.79e-05	6.73e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—breast cancer	1.77e-05	6.67e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTEN—breast cancer	1.54e-05	5.82e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CA—breast cancer	1.09e-05	4.1e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKT1—breast cancer	8.89e-06	3.35e-05	CbGpPWpGaD
